ELTX•benzinga•
Elicio Therapeutics FY 2024 GAAP EPS $(4.25) Misses $(3.56) Estimate, As Of December 31, 2024, Cash And Cash Equivalents Were $17.6M. Including $10M In Gross Proceeds From January 2025 Registered Direct Offering, The Company Expects Cash Runway Into Q4 20
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 31, 2025 by benzinga